- Home
- FEMY vs BTTC Comparison
FEMY vs BTTC Comparison
Compare FEMY & BTTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- BTTC
- Stock Information
- Founded
- FEMY 2004
- BTTC 1990
- Country
- FEMY United States
- BTTC Malaysia
- Employees
- FEMY N/A
- BTTC N/A
- Industry
- FEMY Medical/Dental Instruments
- BTTC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEMY Health Care
- BTTC Health Care
- Exchange
- FEMY Nasdaq
- BTTC Nasdaq
- Market Cap
- FEMY 12.5M
- BTTC 12.3M
- IPO Year
- FEMY 2021
- BTTC N/A
- Fundamental
- Price
- FEMY $0.60
- BTTC $8.00
- Analyst Decision
- FEMY Strong Buy
- BTTC
- Analyst Count
- FEMY 3
- BTTC 0
- Target Price
- FEMY $7.33
- BTTC N/A
- AVG Volume (30 Days)
- FEMY 6.9M
- BTTC 1.8M
- Earning Date
- FEMY 11-11-2025
- BTTC 01-01-0001
- Dividend Yield
- FEMY N/A
- BTTC N/A
- EPS Growth
- FEMY N/A
- BTTC N/A
- EPS
- FEMY N/A
- BTTC N/A
- Revenue
- FEMY $1,887,016.00
- BTTC N/A
- Revenue This Year
- FEMY $103.55
- BTTC N/A
- Revenue Next Year
- FEMY $148.13
- BTTC N/A
- P/E Ratio
- FEMY N/A
- BTTC N/A
- Revenue Growth
- FEMY 98.61
- BTTC N/A
- 52 Week Low
- FEMY $0.31
- BTTC $5.48
- 52 Week High
- FEMY $1.80
- BTTC $39.00
- Technical
- Relative Strength Index (RSI)
- FEMY 59.98
- BTTC N/A
- Support Level
- FEMY $0.34
- BTTC N/A
- Resistance Level
- FEMY $0.92
- BTTC N/A
- Average True Range (ATR)
- FEMY 0.06
- BTTC 0.00
- MACD
- FEMY 0.05
- BTTC 0.00
- Stochastic Oscillator
- FEMY 50.50
- BTTC 0.00
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.